This, in turn, would activate BTIC marker OCT3/4, a direct target of HIF-2 α, along with BTIC marker SOX2, and the critical pluripotent stem cell inducer–MYCC, an onco-protein whose increased expression plays a central role in multiple aspects of tumor cell biology [25–32]. The gene discussed is MYC; the disease is neoplasm.